BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BioCentury | Sep 27, 2019
Product Development

Reading into the first wave of neoantigen results

The first clinical data from neoantigen vaccine companies have started to answer questions about the best way to quickly gauge whether patients are responding. The lessons include how to design combination trials that point to...
BC Extra | Apr 23, 2019
Company News

Pilot program for GSK's malaria vaccine starts in Malawi

WHO launched a planned pilot program of GSK's malaria vaccine RTS,S in Malawi on Tuesday with the goal of informing the organization's policy recommendations for broader use of the vaccine. The organization will also roll...
BC Innovations | Apr 18, 2019
Translation in Brief

Agenus scales the AI ALPS

Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data....
BC Extra | Mar 22, 2019
Company News

Management tracks: Mirum, Novocure

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018...
BC Innovations | Feb 20, 2019
Distillery Therapeutics

Endocrine/metabolic

INDICATION: Diabetes Mouse studies suggest agonizing GITR could help treat insulin resistance. In genetic and high-fat diet-induced mouse models of insulin resistance, a GITR agonist mAb increased glucose tolerance and insulin sensitivity and decreased fasting...
BC Week In Review | Feb 7, 2019
Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
BC Extra | Feb 5, 2019
Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
BC Week In Review | Feb 1, 2019
Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) said Jan. 29 that is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is...
BC Extra | Jan 29, 2019
Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is the first of its...
Items per page:
1 - 10 of 484
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BioCentury | Sep 27, 2019
Product Development

Reading into the first wave of neoantigen results

The first clinical data from neoantigen vaccine companies have started to answer questions about the best way to quickly gauge whether patients are responding. The lessons include how to design combination trials that point to...
BC Extra | Apr 23, 2019
Company News

Pilot program for GSK's malaria vaccine starts in Malawi

WHO launched a planned pilot program of GSK's malaria vaccine RTS,S in Malawi on Tuesday with the goal of informing the organization's policy recommendations for broader use of the vaccine. The organization will also roll...
BC Innovations | Apr 18, 2019
Translation in Brief

Agenus scales the AI ALPS

Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data....
BC Extra | Mar 22, 2019
Company News

Management tracks: Mirum, Novocure

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018...
BC Innovations | Feb 20, 2019
Distillery Therapeutics

Endocrine/metabolic

INDICATION: Diabetes Mouse studies suggest agonizing GITR could help treat insulin resistance. In genetic and high-fat diet-induced mouse models of insulin resistance, a GITR agonist mAb increased glucose tolerance and insulin sensitivity and decreased fasting...
BC Week In Review | Feb 7, 2019
Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
BC Extra | Feb 5, 2019
Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
BC Week In Review | Feb 1, 2019
Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) said Jan. 29 that is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is...
BC Extra | Jan 29, 2019
Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is the first of its...
Items per page:
1 - 10 of 484